Anti-Human CD85j (ILT2) SAFIRE Purified

Grouped product items
SizePrice Qty
100 ug
$200.00

Additional HP-F1 Formats

Cat.No.FormatStarting From
62111-25SAFIRE Purified$ 200.00
Catalog Number : 62111-25

description

The HP-F1 monoclonal antibody reacts with human CD85j, a 110 kDA single transmembrane glycoprotein. The CD85 molecules encompass a large immunoregulatory family called Leuokocyte Immunoglobulin-like Receptors (LIRs) and Ig-Like Transcripts (ILTs). CD85j is also knows as Ig-like transcpript (ILT2) and leukocyte Ig-like receptor (LIR-1). It is expressed on subsets of NK, B and T cells and on myeloid cells such as monocytes and dendritic cells. CD85j is involved in viral infections.

Additional Information

Clone:
HP-F1
Format:
SAFIRE Purified
Applications:
FC, FA
Reactivity:
Human
Isotype:
Mouse IgG1, kappa
Research Interest:Adaptive Immunity, Innate Immunity
Cell Type:T Cells, Macrophage / Monocyte, Dendritic Cells, NK and NKT Cells
Application:FC, FA
Clone:HP-F1
Preparation:
The product should be stored undiluted at 4°C. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography.
Formulation:
Phosphate-buffered aqueous solution, ph7.2.
References:

Colonna, M., Navarro, F., Bellón, T., Llano, M., García, P., Samaridis, J., ... & López-Botet, M. (1997). A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. The Journal of experimental medicine186(11), 1809-1818.

Bellón, T., Kitzig, F., Sayós, J., & López-Botet, M. (2002). Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor. The Journal of Immunology168(7), 3351-3359.

Tenca, C., Merlo, A., Merck, E., Bates, E. E., Saverino, D., Simone, R., ... & Ciccone, E. (2005). CD85j (leukocyte Ig-like receptor-1/Ig-like transcript 2) inhibits human osteoclast-associated receptor-mediated activation of human dendritic cells. The Journal of Immunology174(11), 6757-6763.

© BioGems International, Inc. All rights reserved.